RNS Number : 7248F
MicroSalt PLC
06 March 2024
 

A blue and white sign Description automatically generated

 

6 March 2024

MicroSalt plc

("MicroSalt" or the "Company")

 

Intellectual Property ("IP") Update

 

MicroSalt plc, (AIM: SALT) a company producing full-flavour, low-sodium salt for food manufacturers and consumers, is pleased to announce that it has received a Notice of Allowance from the United States Patent and Trademark Office for Patent Application No. 18/175,028.

 

The Patent Application entitled Low Sodium Salt Composition, concerns the production of MicroSalt, a low-sodium salt that adheres better to foods than a traditional salt (which is not adhered to a carrier particle).

 

Receipt of a Notice of Allowance indicates that the claims in the patent application are patentable. MicroSalt expect the patent will be granted upon completion of certain administrative matters in short course. Once granted, the patent is expected to expire in 2039.

 

This Notice of Allowance relates to one of the 14 pending patent applications described in the Company's admission document dated 27 January 2024. MicroSalt also has counterpart patent applications with claims directed to similar subject matter as the Patent Application 18/175,028 pending in countries including China, Chile, Australia, Brazil, Europe, Canada, Japan, Russia, Mexico, India and Hong Kong.   

 

MicroSalt also owns a previously issued United States patent directed to its salt carrier product and production processes, and a United States provisional patent application directed to additional innovations.

 

Rick Guiney, CEO of Microsalt, said:

 

"This Notice of Allowance further strengthens our IP position in the global low sodium market whilst providing additional evidence of our thought leadership position in the battle to lower sodium consumption worldwide."

 

 For more information, please visit www.microsaltinc.co, follow on X @microSaltPLC or contact:

 

MicroSalt plc

Via Flagstaff

Rick Guiney, CEO 


 

 


Zeus (Nominated Adviser and Broker)                               

David Foreman / James Edis (Investment Banking)

Dom King (Corporate Broking), Rupert Woolfenden (Sales)

 

            +44 (0)20 3829 5000

Flagstaff PR (Financial IR/FPR)   

+44 (0)20 7129 1474

Tim Thompson / Alison Allfrey / Anna Probert        

microsalt@flagstaffcomms.com


 

 

Notes to Editors

 

MicroSalt® produces a patented full-flavour, low-sodium salt for food manufacturers and consumers.

 

MicroSalt is a major potential disruptor in the food market, thanks to its micron sized particles which deliver the same sense of saltiness to a wide range of foods but with approximately 50% less sodium. Excess sodium consumption is a significant contributor to cardiovascular disease and MicroSalt's solution meets the rising demand for healthier alternatives to traditional salt. The WHO has set a target for reducing global sodium intake by 30% by 2025, which it estimates will save 7 million lives by 2030.

 

Each year, cardiovascular disease costs the UK £19 billion - if the average salt intake was reduced by one gram per day, it has been estimated that 4,147 lives and £288 million would be saved each year in the UK. As a nation, the UK consumes 183 million kilograms of salt each year, and 70% of the typical person's sodium intake is hidden in processed foods.

 

Operational since 2018, MicroSalt uses a patent-protected technology which helps create high barriers to entry within the reduced-sodium salt market.

 

The Directors believe that MicroSalt is well positioned to capture growth in the low sodium market, which is expected to grow exponentially, and that there is also scope to enter the larger salt market.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUVUORSRUORUR